Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products.

Ms. Bulger has 27 years of experience in drug development in the pharmaceutical industry, conducting clinical research and providing strategic medical marketing support in dermatology, rheumatology, osteoporosis, and CNS. Most recently, Ms. Bulger held the position of Director Medical Affairs at Stiefel, a GSK company. In this role, she was responsible for medical affairs activities for Stiefel Global and Canada for 35 dermatology products. Previously, Ms. Bulger was Director Medical and Regulatory Affairs at Barrier Therapeutics and Director Medical Affairs at Hoffman-La Roche. She served as President of the Canadian Dermatology Industry Association from 2005 to 2008.

In addition to this appointment, Cipher promoted Peter Weiler to the position of Vice President, Business Development and Linda Angaritis to the position of Vice President, Global Regulatory Compliance and Quality. Mr. Weiler has been with Cipher since 2008 and leads the Company's expanding business development activities. Ms. Angaritis joined Cipher in 2013 and is responsible for the overall regulatory compliance and quality functions across the business.

"We are pleased to welcome Lynne to Cipher's management team," said Shawn O'Brien, President and CEO at Cipher. "Her deep experience in dermatology clinical development and strong customer relationships will be valuable assets as we execute our strategy to build our dermatology pipeline, bring new products to market and support our marketing efforts. I'd also like to congratulate Peter and Linda on their expanded roles with the organization. We have a strong and growing management team to support our strategic growth plans."